Departments for Radiation Oncology, Charité School of Medicine and University Hospital of Berlin, Augustenburger Platz 1, 13353, Berlin, Germany,
Strahlenther Onkol. 2014 Jun;190(6):533-7. doi: 10.1007/s00066-014-0646-9. Epub 2014 Mar 4.
Local tumor control and functional outcome after linac-based stereotactic radiosurgery (SRS) and fractionated stereotactic radiotherapy (FSRT) for vestibular schwannoma (VS) were assessed.
In all, 250 patients with VS were treated: 190 patients with tumors < 2 cm diameter underwent SRS and 60 patients with tumors >2 to 3.5 cm underwent FSRT. Dose prescription for all cases with SRS (n = 190, 76 %) was 13.5 Gy. For FSRT, mainly two hypofractionated schedules (n = 60, 24 %) with either 7 fractions of 5 Gy (total dose: 35 Gy; n = 35) or 11 fractions of 3.8 Gy (total dose: 41.8 Gy; n = 16) were used. The primary endpoint was local tumor control. Secondary endpoints were symptomatic control and morbidity.
The median follow-up was 33.8 months. The 3-year local tumor control was 88.9 %. Local control for SRS and FSRT was 88 and 92 %, respectively. For FSRT with 35 and 41.8 Gy, local control was 90 and 100 %, respectively. There were no acute reactions exceeding grade I. In 61 cases (24.4 % of the entire cohort), trigeminal neuralgia was reported prior to treatment. At last follow-up, 16.3 % (10/61) of those patients reported relief of pain. Regarding facial nerve dysfunction, 45 patients (18 %) presented with symptoms prior to RT. At the last follow-up, 13.3% (6/45) of those patients reported a relief of dysesthesia.
Using SRS to treat small VS results in good local control rates. FSRT for larger lesions also seems effective. Severe treatment-related complications are not frequent. Therefore, image-guided stereotactic radiotherapy is an appropriate alternative to microsurgery for patients with VS.
评估基于直线加速器的立体定向放射外科(SRS)和分次立体定向放射治疗(FSRT)治疗前庭神经鞘瘤(VS)后的局部肿瘤控制和功能结果。
共治疗 250 例 VS 患者:190 例肿瘤直径<2cm 的患者行 SRS 治疗,60 例肿瘤直径 2-3.5cm 的患者行 FSRT 治疗。所有 SRS 病例(n=190,76%)的处方剂量为 13.5Gy。FSRT 主要采用两种低分割方案(n=60,24%),分别为 7 次 5Gy(总剂量:35Gy;n=35)或 11 次 3.8Gy(总剂量:41.8Gy;n=16)。主要终点为局部肿瘤控制。次要终点为症状控制和发病率。
中位随访时间为 33.8 个月。3 年局部肿瘤控制率为 88.9%。SRS 和 FSRT 的局部控制率分别为 88%和 92%。FSRT 采用 35Gy 和 41.8Gy 时,局部控制率分别为 90%和 100%。无急性反应超过 I 级。在 61 例(整个队列的 24.4%)患者中,治疗前报告有三叉神经痛。最后一次随访时,16.3%(10/61)的患者报告疼痛缓解。关于面神经功能障碍,45 例(18%)患者在 RT 前有症状。最后一次随访时,13.3%(6/45)的患者报告感觉异常缓解。
使用 SRS 治疗小 VS 可获得良好的局部控制率。FSRT 治疗较大病变也似乎有效。严重的治疗相关并发症并不常见。因此,对于 VS 患者,图像引导立体定向放射治疗是手术的一种合适替代方法。